Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Alexandra Stine

Physician Assistant Moosic, PA Physician Assistant

NPI 1295198950 CMS profile 10482939

340 Montage Mountain Rd, Moosic, PA 18507

Open in the dashboard

General payments

$8,932

590 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexandra Stine of Moosic, PA is reported in the CMS Open Payments database as having received $8,932 across 590 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,512 97
2024 General $1,893 124
2023 General $2,385 165
2022 General $2,360 154
2021 General $781 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexandra Stine
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Alexandra Stine were reported at $1,512. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Alexandra Stine Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $781 $132 $37–$438 $132
2022 $2,360 $155 $48–$522 $149
2023 $2,385 $167 $52–$557 $160
2024 $1,893 $178 $55–$600 $164
2025 $1,512 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Teva Pharmaceuticals USA, Inc. $1,107 77 payments
  2. ITI, Inc. $1,065 62 payments
  3. Alkermes, Inc. $792 43 payments
  4. Janssen Pharmaceuticals, Inc $743 54 payments
  5. Neurocrine Biosciences, Inc. $700 51 payments
  6. AbbVie, Inc. $642 55 payments
  7. Bausch Health US, LLC $494 28 payments
  8. Otsuka America Pharmaceutical, Inc. $439 25 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $427 30 payments
  10. Lundbeck LLC $386 32 payments
  11. Other $2,136 133 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,820 587 payments
  2. Education $112 3 payments
Products named General payments · program years 2021–2025
  1. CAPLYTA $1,035 60 payments
  2. LYBALVI $792 43 payments
  3. ARISTADA Cns $792 43 payments
  4. ARISTADA Cns $792 43 payments
  5. INGREZZA $630 46 payments
  6. ARISTADA Cns $541 29 payments
  7. ARISTADA Cns $541 29 payments
  8. APLENZIN $494 28 payments
  9. WELLBUTRIN $492 26 payments
  10. Austedo XR $441 35 payments
  11. Other $6,446 443 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 67 drugs

Part D claims

4,286

Median for Physician Assistant: 241

Drug cost

$454,126

Median for Physician Assistant: $4,110

Branded share of claims

19.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 14 $119,880
Vraylar Cariprazine Hcl Brand 43 $69,434
Abilify Maintena Aripiprazole Brand 19 $55,574
Wellbutrin Xl Bupropion Hcl Brand 12 $29,710
Trintellix Vortioxetine Hydrobromide Brand 29 $26,722
Rexulti Brexpiprazole Brand 18 $23,246
Lurasidone Hcl Generic 42 $11,879
Nuedexta Dextromethorphan Hbr/Quinidine Brand 12 $9,936
Aripiprazole Generic 92 $8,323
Effexor Xr Venlafaxine Hcl Brand 12 $8,157

The 10 drugs with the highest cost, of 67 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$27,868

Medicare's payments for the services billed

Medicare patients

107

Average age 65

Services billed

450

76 women, 31 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 69%
High blood pressure 61%
Arthritis 37%
COPD 27%
Diabetes 21%
Ischemic heart disease 19%
Osteoporosis 16%
Alzheimer's or dementia 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $141
  • Otsuka America Pharmaceutical, Inc. $91
$232 18 —
CAPLYTA
  • ITI, Inc. $229
$229 — —
Auvelity
  • Axsome Therapeutics, Inc. $229
$229 — —
VRAYLAR
  • AbbVie, Inc. $191
$191 43 —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $136
$136 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

590 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record